Cordis Corp. v. Boston Scientific Corp.
Cordis Corp. v. Boston Scientific Corp.
070rehearing
ON PETITION FOR REHEARING
Co-defendants Boston Scientific Corp. and Boston Scientific Scimed, Inc., (collectively, “BSC”) have filed a petition for panel rehearing and for rehearing en banc. Among its arguments, BSC asserts that rehearing is warranted because the panel failed to direct the district court to grant BSC a new trial on the issue of obviousness with respect to claim 44 of U.S. Patent No. 4,739,762 (“the '762 patent”) following this court’s reversal of the district court’s order invalidating that claim on other grounds.
The district court’s familiarity with the proceedings in this case puts it in the best position to determine whether BSC’s defense of obviousness with respect to claim 44 has been waived and, if not, what further proceedings are appropriate. We issue this supplemental order to make clear that this court’s mandate was not intended to resolve the issue of waiver and accordingly does not have the effect of depriving the district court of the authority to determine whether it should conduct further proceedings addressing the merits of the issue of the obviousness of claim 44.
SO ORDERED.
Reference
- Full Case Name
- CORDIS CORPORATION v. BOSTON SCIENTIFIC CORPORATION and Boston Scientific Scimed, Inc. (formerly known as Scimed Life Systems, Inc.), Defendants-Appellants Medtronic Ave, Inc. v. Cordis Corporation, Johnson and Johnson, and Expandable Grafts Partnership, Defendants-Appellees Boston Scientific Corporation and Boston Scientific Scimed, Inc. (formerly known as Scimed Life Systems, Inc.) v. Ethicon, Inc., Cordis Corporation, and Johnson & Johnson Interventional Systems Co., Defendants-Cross
- Cited By
- 1 case
- Status
- Published